Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company focused on MASH, Madrigal uses SEC reports to present detailed information on its financial performance, capital structure, risk factors, and material corporate events related to Rezdiffra (resmetirom) and its broader pipeline.
Investors can review current reports on Form 8-K where Madrigal announces quarterly and annual financial results, material financing arrangements, licensing agreements, and other significant events. Recent 8-K filings describe quarterly earnings releases, a senior secured credit facility with funds managed by Blue Owl Capital, and the use of proceeds to repay and terminate a prior loan agreement, as well as shareholder voting results from the annual meeting.
In addition to 8-Ks, users can access Madrigal’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) to study revenue from Rezdiffra, research and development spending on the MAESTRO clinical program and pipeline assets such as the licensed oral GLP-1 receptor agonist and ervogastat, and detailed risk factor disclosures. These filings also discuss regulatory considerations around MASH indications, ongoing Phase 3 outcomes trials, and forward-looking statements about the company’s strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from long filings, helping readers quickly understand changes in liquidity, debt covenants, operating expenses, and other important metrics without reading every page. Users can also track executive and director-related disclosures when Forms 3, 4, and 5 appear in the SEC stream, providing visibility into equity awards and other reportable transactions.
By combining real-time EDGAR updates with AI-generated insights, this page offers a practical way to follow how Madrigal’s clinical progress in MASH, commercialization of Rezdiffra, and financing decisions are reflected in its official SEC reporting.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,263 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $15,120,418.50 and 22,289,014 shares outstanding. The filing states the shares were acquired and are to be sold on 08/12/2025 following an exercise of stock options, with payment in cash. The notice also lists multiple recent 10b5-1 insider sales by Rebecca Taub and Paul A. Friedman in July–August 2025, including large transactions on 07/16/2025. Several identifying fields for the filer/issuer in the provided form appear blank.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,605 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $15,239,947.50 and 22,289,014 shares outstanding. The filing states the shares were acquired by exercise of stock options on 08/12/2025 and paid in cash, with an approximate sale date of 08/12/2025. The form also lists multiple recent 10b5-1 sales by insiders Rebecca Taub and Paul A. Friedman in July–August 2025 that generated substantial gross proceeds, and the filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 3,203 common shares acquired the same day by exercise of stock options. The shares have an aggregate market value of $1,107,373.19 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists total shares outstanding of 22,289,014, so the proposed sale represents a small fraction of the company stock. The acquisition was paid in cash. The filing also discloses multiple 10b5-1 sales by Rebecca Taub and Paul A. Friedman in mid-July 2025 totaling 60,377 shares with combined gross proceeds of $21,316,990.08.
Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 reports a proposed sale of 3,200 common shares through Morgan Stanley Smith Barney LLC on 08/11/2025 for an aggregate market value of $1,106,336.00. The filing shows 22,289,014 shares outstanding and lists NASDAQ as the exchange.
The shares were acquired on 08/11/2025 by exercise of stock options from the issuer, paid in cash. The filing also discloses multiple recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman during July 2025 totaling 60,377 shares with combined gross proceeds of about $21.3 million.
Madrigal Pharmaceuticals’ Q2-25 10-Q shows the company’s first full quarter of Rezdiffra commercialization driving a dramatic top-line inflection. Net product revenue reached $212.8 m for the quarter and $350.1 m YTD, versus $14.6 m in the prior-year periods. Cost of sales was only $13.6 m YTD, yielding a gross margin above 96%, but heavy commercial scale-up spending pushed operating expenses to $476.6 m (up 45% YoY). Consequently, the H1 operating loss narrowed to $126.5 m from $314.6 m, with a GAAP net loss of $115.5 m (-$5.22/sh).
Cash, cash equivalents and marketable securities totalled $802.0 m at 30 Jun 25, down modestly from $931.3 m at year-end after $136 m operating cash burn and $212 m net investment inflow. Inventory rose to $63.5 m as launch stock builds. Accounts receivable increased to $79.2 m, and gross-to-net reserves expanded to $52.3 m, reflecting payer rebates and copay assistance.
Liabilities were $319.4 m, including $118.4 m outstanding on the Hercules loan. Post-quarter, Madrigal replaced this facility with a new $350 m initial draw (up to $500 m total) Blue Owl secured term loan maturing 2030, subject to a $100 m minimum cash covenant.
22.29 m shares were outstanding on 1 Aug 25. Management emphasises ongoing U.S. launch execution, EU regulatory progress, and outcome trials needed for full Rezdiffra approval and label expansion.